ClinicalTrials.gg
Not yet recruitingNCT07150988Updated Sep 2, 2025

A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of HSK44459 dose level 1 and HSK44459 dose level 2 in Psoriasis, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Planned enrollment
98th of 182
150 · median 171
Started
2025
with 35 others
Phase 2
42 of 206
11 open now
Primary completion
2026-11
later than 33 of 65 live
Registered
171st of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 98th largest by planned enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 42 in phase 2, reaches primary completion later than 33 of the 65 other live ones, and was the 171st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.

Read the detailed description

Patients with moderate to severe plaque psoriasis will be randomized into 3 cohorts (dose level 1, dose level 2 and placebo). Approximately 150 subjects will be enrolled. This study includes an 16-week treatment Period, then a 4-week safety visit period.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand and voluntarily participate this trial, and sign the form;
  • Age≥18 years, regardless of gender;
  • Plaque psoriasis;
  • A candidate for systemic therapy;
  • Agree to use a highly effective method(s) of from the signing of the informed consent form to 3 months post-treatment.

Exclusion criteria

Exclusion Criteria:

  • Can not discontinue the prohibited medications specified in the protocol before the first dose and throughout the entire study period;
  • Laboratory abnormalities with clinical significance;
  • Forms of psoriasis other than chronic plaque-type;
  • Presence of other dermatological or diseases;
  • Presence of active infection requiring systemic therapy;
  • Has undergone or plans to undergo major surgery;
  • History of cardiovascular or cerebrovascular diseases;
  • History of suicide attempts or major psychiatric disorders;
  • History of malignant tumors;
  • History of gastrointestinal surgery or diseases that may have impact on the study;
  • History of drug abuse, illicit drug use, or alcohol abuse;
  • History of severe drug allergies;
  • Pregnant or lactating women;
  • Subjects with any other factor considered by the investigator to be ineligible for participation in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    HSK44459 dose level 1

    HSK44459 dosage 1 oral administration

    Drug: HSK44459 dose level 1

  • Experimental
    HSK44459 dose level 2

    HSK44459 dose level 2 oral administration

    Drug: HSK44459 dose level 2

  • Placebo comparator
    Placebo control

    placebo oral administration

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who have ≥75% reduction in PASI (PASI-75).

    The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 16.

    Time frame: 16 weeks

Secondary outcomes

  1. Proportion of subjects achieving an IGA score of clear 0 or 1 with ≥2 point reduction from baseline.

    Proportion of subjects achieving an IGA score of clear 0 or 1 with ≥2 point reduction at week 2, 4, 8, 12 and 16 from baseline.

    Time frame: 2, 4, 8, 12 and 16 weeks

  2. Proportion of subjects who have ≥75% reduction in PASI (PASI-75).

    The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 2, 4, 8 and 12.

    Time frame: 2, 4, 8 and 12 weeks

  3. Proportion of subjects who have ≥50% reduction in PASI (PASI-50).

    The proportion of subjects who have a reduction of 50% or more from baseline in the psoriasis area-and-severity index score (PASI-50 at week 2, 4, 8, 12 and 16.

    Time frame: 2, 4, 8, 12 and 16 weeks

  4. Proportion of subjects who have ≥90% reduction in PASI (PASI-90).

    The proportion of subjects who have a reduction of 90% or more from baseline in the psoriasis area-and-severity index score (PASI-90) at week 2, 4, 8, 12 and 16.

    Time frame: 2, 4, 8, 12 and 16 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Nov 2026, 13 months later.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 13 months is close to that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartEst.
Sep 26, 2025
Primary completionEst.
Nov 6, 2026
CompletionEst.
Nov 6, 2026
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07150988
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Sep 26, 2025 (estimated)
Primary completion
Nov 6, 2026 (estimated)
Completion
Nov 6, 2026 (estimated)
Last update
Sep 2, 2025

Study contacts

Yong Cao
Contact
caoyong@haisco.com
028-67258779

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK44459

Start the discussion